From Nasdaq Stock Market:

According to RTTNews, 55 novel drugs have been approved by the U.S. regulatory agency in 2023, the second-highest tally recorded. Ligand Pharmaceuticals Inc.’s Berdazimer gel, also proposed for the treatment of molluscum contagiosum, is up for an FDA decision on January 5, 2024. Then, on January 12, 2024, the FDA decision is due on Astellas Pharma’s Zolbetuximab, a first-in-class chimeric IgG1 monoclonal antibody. Merck & Co. Inc. is expecting a decision on January 20, 2024, for its blockbuster cancer drug Keytruda for another indication. Sanofi is expecting a decision on January 31, 2024, to expand the use of Dupixent in the treatment of eosinophilic esophagitis.



Read more: Biotech Stocks Facing FDA Decision In January 2024